• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Sciton Unveils mJOULE Platform Featuring MOXI and BBL HERO


Sciton recently announced its new platform, mJOULE, featuring a new non-ablative fractional treatment and IPL technology for treating sun damage and anti-aging.

Sciton Inc., aesthetic laser and light manufacturer, recently unveiled the dual-wavelength mJOULE platform, featuring a new non-ablative fractional treatment called MOXI and intense pulsed light (IPL) technology, BBL HERO.

MOXI was created for patients looking to correct signs of sun damage and aging by reducing uneven pigmentation and improving the tone and texture of the skin, according to the press release.

With visible improvements after a single 30-minute treatment, MOXI delivers non-ablative laser energy 365 days a year, no matter the patient’s age or skin type, according to Sciton.

"1927 nm is a winner, BBL plus 1927nm (MOXI) equals an awesome, delegatable treatment," says Elizabeth L. Tanzi, M.D., FAAD, Director Capital Laser and Skin Care, in the press release.

BBL HERO (High Energy Raid Output), a powerful IPL broadband light also featured on the mJOULE platform, can be used to treat the entire body with Forever Young BBL+ and Forever Body, delivering tonal and textural improvements to the target area, according to the company.

BBL HERO, Sciton says, also allows practitioners to treat the entire body at four times the speed, three times the peak power and two times the cooling capacity.

"At Sciton we work hand in hand with our physician partners to drive visionary innovation that is founded on science and uncompromised in quality," says Robb Brindley, Sciton Vice President of North American Sales. "We are proud to lead the industry, leaving competitors by the wayside with proven technologies that benefit practices and patients alike. The future of aesthetic medicine is brighter than ever, and we are well positioned to release multiple products during a critical time in our industry."

Related Videos
© 2023 MJH Life Sciences

All rights reserved.